Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Posted: February 24, 2023 at 12:14 am

Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers

See original here:
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Related Posts